Zacks ranks ReGenX Biosciences in the Medical - Biomedical and Genetics industry.
4 reports, 2 independent
Updated Aug 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Zacks ranks ReGenX Biosciences in the Medical - Biomedical and Genetics industry.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
ReGenX Biosciences (United States)
company in Washington D.C., United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksAre Options Traders Betting on a Big Move in Regenxbio Stock? Investors in REGENXBIO Inc. RGNX need to pay close attention to the stock based on moves in the options market lately. That is because th
- Simply Wall St.These Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Forecasts Explore REGENXBIO's Fair Values from the Community and select yours Today is shaping up negative f
- ZacksRegenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates Regenxbio (RGNX) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a